Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...
New York State Psychiatric Institute, New York, New York, United States
University of California, San Francisco, California, United States
The Second Xiangya Hospital of Central University, Changsha, Hunan, China
The Second Xiangya Hospital of Central University, Changsha, Hunan, China
The first hospital of Hebei Province University, Shijiazhuang, Hebei, China
Institute of mental health, Peking University, Beijing, Beijing, China
BC Mental Health & Addictions Research Institute, Vancouver, British Columbia, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.